Abbvie (ABBV) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Phase 1 AbbVie study, officially titled “A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma,” aims to test safety and early benefit of ABBV-438 in hard-to-treat multiple myeloma, a setting with high unmet need and meaningful upside if results are positive.
The trial tests ABBV-438, an intravenous drug given alone to adults whose multiple myeloma has come back or stopped responding to other therapies. The goal is to find a safe dose, see how the drug moves through the body, and look for early signs that it can control the cancer and support a broader development plan.
The study is interventional and non-randomized, meaning all participants receive ABBV-438 rather than standard care or placebo, and results focus on safety and early activity, not comparisons. It uses a parallel group, open-label design, so both doctors and patients know the dose level, and the main purpose is to find the right dose for future Phase 2 trials.
The trial began enrolling after first submission on 9 Feb 2026, marking the start of human testing and an early risk point for ABBV’s pipeline story. The latest update on 13 Apr 2026 shows the protocol is active and refined, while primary and final completion dates are still in the future, signaling a long 69.5‑month timeline before mature efficacy data.
For investors, this update reinforces AbbVie’s push to deepen its oncology portfolio beyond current blockbusters, with ABBV-438 a high-risk, high-reward early asset that could support long-term growth if signals are strong. The multiple myeloma space is crowded, with players like JNJ, BMY and others, but any novel, tolerable option in relapsed disease could command premium pricing and help sentiment around ABBV’s innovation engine.
The ABBV-438 study in relapsed or refractory multiple myeloma remains active and in early stages, and investors can track ongoing updates and full protocol details on the ClinicalTrials portal.
To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.